Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

R Bellmann, P Smuszkiewicz - Infection, 2017 - Springer
Introduction Because of the high mortality of invasive fungal infections (IFIs), appropriate
exposure to antifungals appears to be crucial for therapeutic efficacy and safety. Materials …

Echinocandin antifungal drugs

DW Denning - The Lancet, 2003 - thelancet.com
The echinocandins are large lipopeptide molecules that are inhibitors of β-(1, 3)-glucan
synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins …

Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of …

OA Cornely, M Hoenigl, C Lass‐Flörl, SCA Chen… - Mycoses, 2019 - Wiley Online Library
Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …

Nosocomial fungal infections: epidemiology, diagnosis, and treatment

J Perlroth, B Choi, B Spellberg - Medical mycology, 2007 - academic.oup.com
Invasive fungal infections are increasingly common in the nosocomial setting. Furthermore,
because risk factors for these infections continue to increase in frequency, it is likely that …

Antifungal therapeutic drug monitoring: established and emerging indications

D Andes, A Pascual, O Marchetti - Antimicrobial agents and …, 2009 - Am Soc Microbiol
The successful management of invasive fungal infections continues to pose a difficult
challenge to clinicians. As the population of at-risk immunocompromised patients increases …

Combination treatment of invasive fungal infections

PK Mukherjee, DJ Sheehan, CA Hitchcock… - Clinical microbiology …, 2005 - Am Soc Microbiol
The persistence of high morbidity and mortality from systemic fungal infections despite the
availability of novel antifungals points to the need for effective treatment strategies …

In Vitro Activity of Caspofungin against Candida albicans Biofilms

SP Bachmann, K VandeWalle, G Ramage… - Antimicrobial agents …, 2002 - Am Soc Microbiol
Most manifestations of candidiasis are associated with biofilm formation on biological or
inanimate surfaces. Candida albicans biofilms are recalcitrant to treatment with conventional …

Caspofungin

SC Deresinski, DA Stevens - Clinical Infectious Diseases, 2003 - JSTOR
Caspofungin, the first inhibitor of fungal β-1, 3 glucan synthesis to receive approval by the
United States Food and Drug Administration, is effective for the treatment of mucosal and …

Caspofungin: the first representative of a new antifungal class

V Letscher-Bru, R Herbrecht - Journal of Antimicrobial …, 2003 - academic.oup.com
Abstract Caspofungin (MK-0991; L-743,872) belongs to the echinocandin family, a new
class of antifungal agents that act on the fungal cell wall by inhibiting glucan synthesis. Data …

Antifungal therapy: new and evolving therapies

Y Nivoix, MP Ledoux… - Seminars in respiratory and …, 2020 - thieme-connect.com
Invasive fungal diseases primarily occur in immunocompromised patients.
Immunosuppression has become more prevalent due to novel treatments, and this has led …